Beacon Pointe Advisors
CUE icon

Beacon Pointe Advisors’s Cue Biopharma CUE Stock Holding History

Beacon Pointe Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-333
Closed -$2.3K – 1948
2026
Q1 		$2.3K Buy
+333
New +$3.11K ﹤0.01% 1829
2025
Q3 		– Sell
-333
Closed -$6.82K – 1412
2025
Q2 		$6.82K Hold
333
– – ﹤0.01% 1248
2025
Q1 		$9.11K Hold
333
– – ﹤0.01% 1212
2024
Q4 		$10.9K Hold
333
– – ﹤0.01% 1196
2024
Q3 		$7.57K Hold
333
– – ﹤0.01% 1219
2024
Q2 		$12.4K Hold
333
– – ﹤0.01% 1259
2024
Q1 		$18.9K Hold
333
– – ﹤0.01% 1343
2023
Q4 		$26.4K Hold
333
– – ﹤0.01% 1306
2023
Q3 		$23K Hold
333
– – ﹤0.01% 1320
2023
Q2 		$36.5K Hold
333
– – ﹤0.01% 1068
2023
Q1 		$35.7K Hold
333
– – ﹤0.01% 1122
2022
Q4 		$28.5K Buy
+333
New +$30.5K ﹤0.01% 1048

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

Beacon Pointe Advisors's CUE Position: Q2 2026 in Review

Beacon Pointe Advisors sold out of Cue Biopharma (CUE) in Q2 2026, closing a stake of 333 shares — an estimated $2.3K sold.

Beacon Pointe Advisors first reported a position in CUE in Q4 2022 and held it in 12 quarters. The position peaked at $36.5K in Q2 2023. 50 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Beacon Pointe Advisors reported no remaining Cue Biopharma position as of Q2 2026 after selling out during the quarter.
  • Beacon Pointe Advisors sold 333 Cue Biopharma shares in Q2 2026, an estimated $2.3K.
  • Beacon Pointe Advisors first reported a position in Cue Biopharma in Q4 2022 and held it in 12 quarters.
  • Beacon Pointe Advisors's Cue Biopharma position peaked at $36.5K in Q2 2023.
  • 50 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.